Eli Lilly Q3 FY25: where the revenue came from and where it went
The whole income statement of Eli Lilly for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Oct 30, 2025
Revenue$17.6B
+54% year over year
Gross profit$14.6B
83% margin
Operating profit$7.4B
42% margin
Net profit$5.6B
32% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 17.6 | 100% | +54% |
| Mounjaro | 6.5 | 37% | +109% |
| Zepbound | 3.6 | 20% | +185% |
| Other revenue | 2.0 | 12% | |
| Verzenio | 1.5 | 8% | +7% |
| Cardiometabolic health | 1.1 | 6% | +1% |
| Trulicity | 1.1 | 6% | −19% |
| Jardiance | 1.0 | 6% | +40% |
| Other oncology | 0.9 | 5% | +9% |
| Cost of revenue | −3.0 | 17% | |
| Gross profit | 14.6 | 83% margin | +2pp |
| SG&A | −2.7 | 16% | −3pp |
| Other | −4.5 | 25% | +0pp |
| Operating profit | 7.4 | 42% margin | +29pp |
| Interest & other costs | −0.1 | ||
| Tax | −1.7 | ||
| Net profit | 5.6 | 32% margin | +23pp |
123 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest